Paysign Q2 2026 Earnings: Pharma Growth Drives 48% Revenue Increase

Paysign (NASDAQ: PAYS) reported Q2 2026 revenue of $28.25 million, up 48.1% year over year, while GAAP diluted EPS increased to $0.11 from $0.02. Pharma patient affordability programs were the main growth driver, and the shift toward pharma revenue helped expand margins as profit grew faster than revenue.

Core earnings data

Revenue increased by $9.17 million from the prior-year quarter, with pharma contributing about three-quarters of that gain. Higher gross margin and slower operating expense growth produced substantial operating leverage, although reported operating income included a $990,000 non-cash fair-value benefit.

The quarter ended June 30, 2026, and the results were released on August 5, 2026.

Adjusted EBITDA is a non-GAAP measure that excludes stock-based compensation and changes in the fair value of contingent consideration, among other EBITDA adjustments.

Business and segment performance

Pharma patient affordability and plasma donor compensation generated nearly all of Paysign’s quarterly revenue. Pharma grew much faster, but plasma also expanded despite operating with fewer customer centers.

Pharma growth reflected the financial contribution from 51 net patient affordability programs added over the preceding 12 months. Paysign ended the quarter with 148 active programs, while processed claims increased approximately 54%. Additional monthly management, setup, claim-processing and support fees also contributed.

Plasma revenue benefited from higher donations and more dollars loaded onto cards. Paysign ended the quarter with 561 plasma centers, down from 607 a year earlier because of customer center closures and the sale of certain centers to a company using another provider. Higher utilization at the remaining locations provided an offset: average monthly revenue per center rose to $7,699 from $7,098, and the average number of loads per center increased.

Across the platform, gross dollar load volume increased 24.3%, while gross spend volume rose 24.2%.

Pharma mix and operating leverage widened margins

Cost of revenue increased 41.4%, slower than the 48.1% increase in revenue. Paysign attributed the higher costs to network activity, call-center support, a new customer service center launched in November 2025 and higher employee costs. The growing share of higher-margin pharma revenue nevertheless lifted gross margin to 63.3%.

Reported operating expenses rose only 5.5% to $10.89 million, but that figure benefited from the $990,000 fair-value adjustment related to the Gamma acquisition’s contingent consideration. Excluding the benefit, operating expenses would have been $11.9 million, up 15.1%, and adjusted operating margin would have been 21.3% rather than the reported 24.8%. The adjusted margin still increased materially from 7.5% a year earlier.

Within expenses, stock-based compensation increased 31.2% to $1.25 million. Depreciation and amortization rose 10.4% to $2.34 million, mainly because of acquired Gamma intangible assets and continued investment in software and processing equipment.

Net income growth also benefited from a lower effective tax rate of 14.5%, compared with 32.1% a year earlier. Paysign said the rate reflected discrete quarterly items and tax benefits associated with stock-based compensation.

Cash and balance sheet

Paysign ended June 2026 with $27.37 million of unrestricted cash and no bank debt. During the first six months of 2026, unrestricted cash increased by $6.31 million, supported by net income, non-cash adjustments and the timing of operating asset and liability payments, partially offset by capital investment and Gamma-related liability payments.

Restricted cash increased by $5.19 million from year-end to $149.11 million. This balance represents funds used for customer card funding and pharmaceutical claim reimbursements and has corresponding current liabilities, distinguishing it from unrestricted corporate cash.

Earnings guidance

Paysign raised its full-year 2026 revenue outlook to $114 million-$117 million and adjusted EBITDA outlook to $35 million-$38 million. The release did not quantify the increase from the company’s previous ranges, but management cited first-half performance, visibility into additional program launches and seasonal trends as support for the revision.

Paysign expects to exit Q3 with 165-170 active patient affordability programs, up from 148 at the end of Q2. Its projected plasma center count of 561-563 points to a largely stable footprint over the next quarter.

Recent insider transactions

The supplied insider data reports 1,373,333 shares classified as purchases across 15 transactions during the past six months, compared with 352,131 shares sold across nine transactions. That produced reported net purchases of 1,021,202 shares, while total insider holdings were listed at 11.51 million shares.

The latest 10 entries consisted of seven sales and three stock awards. All were reported as direct transactions.

The source lists two identical transactions for Joan M. Herman on May 26. The transactions are presented as reported and do not, by themselves, establish insiders’ views about the company’s outlook.

Risks investors should monitor

• Dependence on patient affordability launches: The addition of 51 net programs was the largest revenue driver. Slower launches or weaker retention would affect Paysign’s fastest-growing segment and its revenue mix.
• Plasma center attrition: Plasma revenue grew despite a net reduction of 46 centers, but continued closures or customers moving to other providers could eventually outweigh higher utilization at existing locations.
• Margin sustainability: Q2 gross margin benefited from the pharma mix, while reported operating margin included a $990,000 non-cash gain. Q3 gross margin guidance of 61%-63% is below the Q2 result at the lower and upper ends of the range.
• Patient affordability regulation: Changes affecting copay assistance, accumulator or maximizer programs could directly influence demand for the business that generated the majority of Paysign’s quarterly growth.

Summary

Paysign’s Q2 2026 results were led by rapid expansion in pharma patient affordability programs, while higher utilization helped plasma revenue grow despite fewer centers. The improved revenue mix and operating leverage expanded margins even after excluding a one-time accounting benefit, and unrestricted cash increased with no bank debt. Execution on additional pharma launches, stabilization of the plasma center base and the sustainability of margins are the main items to follow as Paysign works toward its raised full-year outlook.